Abstract
The two major neuropathologic hallmarks of Alzheimers disease (AD) are extracellular Amyloid β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). A number of additional pathogenic mechanisms, possibly overlapping with Aβ plaques and NFTs formation, have been described, including inflammation, oxidative damage, iron disregulation, cholesterol metabolism. The first drugs developed for AD, anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AchEI are approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine. These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. For this reason they are currently termed “disease modifying” drugs. To block the progression of the disease, they have to interfere with pathogenic steps at the basis of clinical symptoms. In this review, current treatment will be summarized and new perspectives discussed. In particular, several approaches will be described, including Aβ deposition interference by Anti-Aβ aggregation agents, vaccination, β- secretase inhibition or Selective Aβ42-lowering agents (SALAs); tau deposition interference by methyl thioninium chloride (MTC); reduction of inflammation and oxidative damage.
Keywords: Alzheimer's disease, Amyloid, tau, inflammation, disease-modifying drugs
Current Aging Science
Title: Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches
Volume: 3 Issue: 1
Author(s): Daniela Galimberti and Elio Scarpini
Affiliation:
Keywords: Alzheimer's disease, Amyloid, tau, inflammation, disease-modifying drugs
Abstract: The two major neuropathologic hallmarks of Alzheimers disease (AD) are extracellular Amyloid β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). A number of additional pathogenic mechanisms, possibly overlapping with Aβ plaques and NFTs formation, have been described, including inflammation, oxidative damage, iron disregulation, cholesterol metabolism. The first drugs developed for AD, anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AchEI are approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine. These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. For this reason they are currently termed “disease modifying” drugs. To block the progression of the disease, they have to interfere with pathogenic steps at the basis of clinical symptoms. In this review, current treatment will be summarized and new perspectives discussed. In particular, several approaches will be described, including Aβ deposition interference by Anti-Aβ aggregation agents, vaccination, β- secretase inhibition or Selective Aβ42-lowering agents (SALAs); tau deposition interference by methyl thioninium chloride (MTC); reduction of inflammation and oxidative damage.
Export Options
About this article
Cite this article as:
Galimberti Daniela and Scarpini Elio, Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches, Current Aging Science 2010; 3 (1) . https://dx.doi.org/10.2174/1874609811003010046
DOI https://dx.doi.org/10.2174/1874609811003010046 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry Preliminary Anti-Coxsackie Activity of Novel 1-[4-(5,6-dimethyl(H)- 1H(2H)-benzotriazol-1(2)-yl)phenyl]-3-alkyl(aryl)ureas
Medicinal Chemistry Drug Effects on Drug Targets: Inhibition of Enzymes by Neuroleptics, Antimycotics,Antibiotics and Other Drugs on Human Pathogenic Amoebas and their Antiproliferative Effects
Recent Patents on Anti-Infective Drug Discovery A DNA Barcoding Based Study to Identify Main Mosquito Species in Taiwan and its Difference from Those in Mainland China
Combinatorial Chemistry & High Throughput Screening Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS
Current Neuropharmacology Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Strategic Selection of Neuroinflammatory Models in Parkinson's Disease: Evidence from Experimental Studies
CNS & Neurological Disorders - Drug Targets Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases
Current Immunology Reviews (Discontinued) Update On Emerging Antivirals For The Management Of Herpes Simplex Virus Infections: A Patenting Perspective
Recent Patents on Anti-Infective Drug Discovery The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Current Pharmaceutical Design Binding Modes of 2-Phenylamino-6-oxopurines to Herpes Simplex Virus Thymidine Kinases
Letters in Drug Design & Discovery Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Plant Phenolic Compounds as Potential Lead Compounds in Functional Foods for Antiviral Drug Discovery
Current Organic Chemistry Lipid-Activated Nuclear Receptors and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Lipoxin and Synthetic Lipoxin Analogs: An Overview of Anti- Inflammatory Functions and New Concepts in Immunomodulation
Inflammation & Allergy - Drug Targets (Discontinued) Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews